Ahlam H.Tolba | Diseases | Women Researcher Award

Prof.Ahlam H.Tolba | Diseases | Women Researcher Award

Mathematical Statistics at Mansoura University, Egypt

Dr. Ahlam H. Tolba is an Associate Professor of Mathematical Statistics at the Faculty of Science, Mansoura University, Egypt. Born in Talya, Al Minufiyah, she has excelled in the field of statistical modeling and reliability theory. With over a decade of academic experience, she has significantly contributed to mathematical research and education, particularly in stochastic processes, competing risks models, and advanced distribution theory. Dr. Tolba is an active member of several scientific associations and serves as a peer reviewer and editorial board member for numerous international journals. She has supervised multiple postgraduate theses and student research projects and has a prolific publication record with over 35 peer-reviewed papers in high-impact journals. Beyond academia, she engages in international workshops and seminars, strengthening her global presence in the field of applied mathematics and statistics.

Professional Profiles

Education

Dr. Ahlam H. Tolba earned all her academic degrees from Mansoura University, Egypt. She completed her Ph.D. in Mathematical Statistics with a thesis on “Statistical Inference for Some Reliability Models.” Prior to that, she obtained her Master’s degree with a thesis focusing on random differential equations and mean square calculus applications. She graduated with a Bachelor’s degree in Statistical and Computer Science, showcasing early proficiency in statistical theory and computational tools. Her education laid a strong foundation for her expertise in statistical modeling, stochastic processes, and reliability analysis. She has also undertaken numerous professional development courses through the Faculty Leadership Development Program (FLDP), covering a broad spectrum of teaching, research, leadership, and academic planning strategies. Her consistent academic progression reflects her dedication to continuous learning and academic excellence.

Professional Experience

Dr. Tolba began her academic journey as a Demonstrator at Mansoura University in 2009, progressing to Assistant Lecturer , and later Assistant Professor . Since January 2024, she has held the title of Associate Professor of Mathematical Statistics. She has taught and upgraded undergraduate and postgraduate courses such as Stochastic Processes, Reliability Theory, and Probability Theory. She has supervised Ph.D. and Master’s theses, alongside several student graduation projects involving statistical programming. Dr. Tolba actively contributes to Mansoura University’s quality assurance, electronic exams, and digital learning platforms. Her administrative and academic experiences are complemented by involvement in international seminars, quality assurance workshops, and conferences. She also serves as an academic advisor and a reviewer/editor for numerous scientific journals. Her career reflects a strong commitment to research, education, student mentoring, and institutional development.

Awards & Honors

While specific named awards were not listed, Dr. Ahlam Tolba’s recognition is evident in her significant roles across academia and research. She is an editorial board member for prestigious international journals like the Journal of Mathematical Techniques and Computational Mathematics, and a volunteer reviewer for MDPI journals such as Symmetry, Sustainability, and Mathematics. Her invited talks, conference presentations, and leadership roles in organizing national and international conferences further reflect her high standing in the mathematical statistics community. Her continuous promotion through academic ranks—culminating in her Associate Professorship in 2024—demonstrates institutional trust and professional respect. Additionally, her participation in elite programs such as Nature Research Academies workshops (e.g., Research Paper Writing, Grant Writing) and her repeated involvement in Egypt Knowledge Bank (EKB) events show national-level acknowledgment of her research expertise and educational impact.

Research Focus

Dr. Tolba’s research is deeply rooted in reliability theory, statistical inference, and survival analysis. She specializes in developing and analyzing new statistical distributions and shock models, with applications in engineering, medicine, and environmental sciences. Her focus areas include competing risks models, progressive censoring, masked data, and multivariate lifetime data. She employs both classical and Bayesian methodologies in her inference work. Notably, her research often intersects with bridge reliability, stress-strength models, and cancer survival analysis. She actively collaborates on projects involving bivariate and multivariate distributions, generalized data structures, and life-testing experiments. Her publication record includes applications to real-world datasets—ranging from industrial systems to medical data—making her contributions both theoretical and applied. Dr. Tolba is also interested in simulation studies, algorithm development for distributional analysis, and statistical computing using R, Python, and MATLAB.

Skills 

Dr. Ahlam H. Tolba possesses a diverse skill set in statistical computing, programming, teaching, and academic supervision. She is proficient in R, Python, SPSS, MINITAB, Maple, MATLAB, Q-Basic, and C++, reflecting her strong computational foundation. In research, she excels in Bayesian and classical estimation, life data analysis, reliability modeling, and simulation studies. She has guided students in practical projects using statistical software and tools. In teaching, she has upgraded and delivered various courses, including Stochastic Processes, Reliability Theory, and Time Series Analysis. Her training also includes quality assurance, strategic planning, scientific publishing, crisis management, and digital transformation. Her leadership and communication skills are evidenced by her role as an academic advisor and workshop facilitator. She is also adept at curriculum development, electronic exam creation, and research grant preparation, making her an all-rounded academic professional.

Publications Top Notes

  1. Title: Modelling the COVID‐19 Mortality Rate with a New Versatile Modification of the Log‐Logistic Distribution
    Authors: AH Muse, AH Tolba, E Fayad, OA Abu Ali, M Nagy, M Yusuf
    Citations: 54
    Year: 2021

  2. Title: An Extended Cosine Generalized Family of Distributions for Reliability Modeling: Characteristics and Applications with Simulation Study
    Authors: Z Mahmood, TM Jawa, N Sayed-Ahmed, EM Khalil, AH Muse, AH Tolba
    Citations: 39
    Year: 2022

  3. Title: New Lifetime Distribution with Applications to Single Acceptance Sampling Plan and Scenarios of Increasing Hazard Rates
    Authors: EQ Chinedu, QC Chukwudum, N Alsadat, OJ Obulezi, EM Almetwally, AH Tolba
    Citations: 31
    Year: 2023

  4. Title: A Unit Half-Logistic Geometric Distribution and Its Application in Insurance
    Authors: AT Ramadan, AH Tolba, BS El-Desouky
    Citations: 31
    Year: 2022

  5. Title: Bayesian and Non-Bayesian Estimation Methods for Simulating the Parameter of the Akshaya Distribution
    Authors: A Tolba
    Citations: 28
    Year: 2022

  6. Title: A New Distribution for Modeling Data with Increasing Hazard Rate: A Case of COVID-19 Pandemic and Vinyl Chloride Data
    Authors: AH Tolba, CK Onyekwere, AR El-Saeed, N Alsadat, H Alohali, OJ Obulezi
    Citations: 24
    Year: 2023

Conclusion

Zhong-Yi Dong | Oncology | Best Researcher Award

Pr. Zhong-Yi Dong | Oncology | Best Researcher Award

Teacher at Universidade Federal do Oeste do Pará, China

Dr. Dong Zhongyi, born in August 1985, is an esteemed oncologist specializing in tumor radiotherapy. With over a decade of experience, he serves as Associate Chief Physician in the Department of Radiotherapy at Southern Hospital, Southern Medical University. He leads the lung cancer subspecialty group and mentors postgraduate students. Dr. Dong has received numerous accolades, including recognition in the “World’s Top 2% Scientists” (2024) and the “Guangdong Special Support Plan for Young Top Talents in Health.” His research contributions include over 20 high-impact publications and multiple national patents. He has been invited to present at international and domestic conferences and has secured major research grants. Dr. Dong actively participates in academic leadership, holding key positions in multiple professional medical committees in Guangdong, China. His work significantly advances the field of oncology, particularly in radiotherapy and immunotherapy for lung cancer.

Professional Profiles📖

ORwID

Education 🎓

Dr. Dong Zhongyi pursued his medical education at prestigious institutions, building a strong foundation in oncology and clinical medicine. He earned his Bachelor of Clinical Medicine from the University of South China, School of Medicine (2004-2009). This early training equipped him with essential medical knowledge and clinical skills. Following his undergraduate studies, he specialized further by obtaining a Master’s degree in Oncology (2009-2012) from Southern Hospital, Southern Medical University. During this time, he developed expertise in cancer treatment and research, particularly in radiotherapy and targeted therapies. Dr.Dong then advanced his academic journey with a Ph.D. in Oncology (2014-2017) from the Lung Cancer Research Institute, Guangdong Provincial People’s Hospital, under the mentorship of Professor Yilong Wu. His doctoral research focused on the molecular mechanisms of immune resistance and tumor microenvironments, providing critical insights into cancer progression and treatment strategies. This work laid the foundation for his impactful contributions to clinical oncology and translational medicine.

Work Experience💼

Dr. Dong Zhongyi has built a distinguished career in oncology, marked by extensive clinical practice, research, and teaching in tumor radiotherapy. He began his professional journey as a Resident Physician (2012-2014) at Xiangtan Central Hospital, Hunan Province, where he gained hands-on experience in patient care and medical oncology. This period helped him develop a strong clinical foundation in cancer treatment. Following this, he advanced to the role of Attending Physician (2017-2022) at Southern Hospital, Southern Medical University, where he further honed his expertise in lung cancer treatment and radiotherapy. His dedication to integrating research with clinical practice significantly improved patient outcomes. Currently, Dr. Dong serves as an Associate Chief Physician (2022-Present) at Southern Hospital, Southern Medical University, where he continues to lead advancements in oncology. In addition to his clinical role, he is deeply involved in medical education, serving as a Master’s Supervisor (2021-Present) and Doctoral Supervisor (2024-Present). Throughout his career, Dr. Dong has remained at the forefront of lung cancer research, pioneering innovative treatment strategies and leading multiple research projects. His commitment to mentoring young medical professionals has played a crucial role in shaping the next generation of oncologists

Awards and Honors 🏆

Dr. Dong Zhongyi has received numerous prestigious awards in recognition of his exceptional contributions to lung cancer research and oncology. He was honored with the “Guangdong Special Support Plan for Young Top Talents in Health,” reflecting his leadership in medical research. In 2024, he was listed among the “World’s Top 2% Scientists,” a testament to his global impact in oncology. His achievements in lung cancer research were further acknowledged when he ranked 41st among China’s Top 100 Schors in Lung Cancer (2022). Additionally, he received the IASLC Developing Nation Award twice, in 2016 and 2020, highlighting his contributions to international lung cancer research. In 2020, Dr. Dong was awarded the First Prize of the Guangdong Natural Science Award, recognizing his groundbreaking work in tumor radiotherapy and cancer treatment. His dedication to advancing oncology has also been supported by prestigious talent programs, including the “National Outstanding Young Scientist Cultivation Plan (Class A)” and the “Excllent Young Scientist Cultivation Plan” by Southern Medical University. These accolades underscore Dr. Dong’s remarkable impact on the field, cementing his status as a leading researcher and clinician in lung cancer treatment and translational medicine.

Skills💡

Dr. Dong Zhongyi is a distinguished expert in oncology research and clinical application, seamlessly integrating cutting-edge research into patient care. His expertise in radiotherapy and immunotherapy has contributed to advanced cancer treatment strategies, improving therapeutic outcomes. With a strong foundation in molecular and translational medicine, he continuously innovates in tumor biology, enhancing precision oncology approaches. As a prolific researcher, Dr. Dong has authored over 20 high-impact scientific papers, demonstrating his excellence in scientific writing and publishing. His commitment to academic mentorship is evident in his role as a supervisor for postgraduate research, nurturing the next generation of oncology professionals. Additionally, his contributions to medical innovation and patents—holding multiple invention patents—underscore his role as a leader in oncology research and education. Through these skills, Dr. Dong continues to drive advancements in cancer treatment and medical science.

Research Focus 🔬

Dr. Dong Zhongyi’s research encompasses both clinical and translational oncology, with a strong focus on advancing lung cancer treatment. His work in radiotherapy and immunotherapy has led to significant advancements in treatment strategies, improving patient survival and quality of life. He has extensively investigated the molecular mechanisms of immune resistance, shedding light on how tumor microenvironments influence therapy effectiveness. Additionally, Dr. Dong has contributed to understanding and mitigating the adverse effects of immunotherapy, developing strategies to enhance patient safety and treatment efficacy. His groundbreaking research has influenced global oncology guidelines and has been cited in expert consensus documents, underscoring his role in shaping the future of cancer care. By refining precision medicine approaches, his work continues to drive innovation in oncology, ultimately improving patient outcomes worldwide.

Conclusion✅

Dr. Dong Zhongyi is a highly deserving candidate for the Best Researcher Award. His groundbreaking contributions to lung cancer research, impressive publication record, and leadership in the oncology community make him a standout researcher. While expanding international collaborations and clinical impact could further enhance his profile, his achievements thus far position him as a strong contender for this prestigious recognition.

Publications Top Notes📚

 

CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

Journal: Nature Communications

Year: 2023

PMID: 36871040

Citations: [Check Citation Data]

PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

Journal: Cancer Research

Year: 2023

PMID: 36512628

Citations: [Check Citation Data]

Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation

Journal: BMC Medicine

Year: 2023

PMID: 36600276

Citations: [Check Citation Data]

Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors

Journal: Cancer Medicine

Year: 2022

DOI: 10.1002/cam4.4818

Citations: [Check Citation Data]

Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer

Journal: BMC Medicine

Year: 2022

PMID: 35410334

Citations: [Check Citation Data]

Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation

Journal: Frontiers in Oncology

Year: 2021

DOI: 10.3389/fonc.2021.772604

Citations: [Check Citation Data]

Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage

Journal: BMC Medicine

Year: 2021

DOI: 10.1186/s12916-021-02194-z

Citations: [Check Citation Data]

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma

Journal: Frontiers in Oncology

Year: 2021

PMID: 34221982

Citations: [Check Citation Data]

Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy

Journal: Cancer Management and Research

Year: 2021

PMID: 34135631

Citations: [Check Citation Data]

Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer

Journal: Oncoimmunology

Year: 2021

PMID: 33996262

Citations: [Check Citation Data]

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC

Journal: Journal for ImmunoTherapy of Cancer

Year: 2020

DOI: 10.1136/jitc-2019-000381

Citations: [Check Citation Data]

Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer

Journal: Theranostics

Year: 2020

DOI: 10.7150/thno.49864

Citations: [Check Citation Data]

HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma

Journal: Scientific Reports

Year: 2019

DOI: 10.1038/s41598-019-49771-0

Citations: [Check Citation Data]

Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer

Journal: Clinical Cancer Research

Year: 2019

DOI: 10.1158/1078-0432.ccr-19-0558

Citations: [Check Citation Data]

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation

Journal: Journal of Thoracic Oncology

Year: 2018

PMID: 30056164

Citations: [Check Citation Data]

VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma

Journal: BMC Cancer

Year: 2018

PMID: 29720116

Citations: [Check Citation Data]

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies

Journal: Journal of Thoracic Oncology

Year: 2017

PMID: 29127022

Citations: [Check Citation Data]

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Journal: Oncoimmunology

Year: 2017

PMID: 29147605

Citations: [Check Citation Data]

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Journal: Clinical Cancer Research

Year: 2017

PMID: 28039262

Citations: [Check Citation Data]

Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer

Journal: The Oncologist

Year: 2017

PMID: 28126915

Citations: [Check Citation Data]

Potential biomarker for checkpoint blockade immunotherapy and treatment strategy

Journal: Tumour Biology

Year: 2016

PMID: 26779629

Citations: [Check Citation Data]

FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3β pathway

Journal: Oncogene

Year: 2013

PMID: 23812429

Citations: [Check Citation Data]

 

Lin Zhou | Diseases | Excellence in Innovation

prof. Dr. Lin Zhou | Diseases | Excellence in Innovation

Dr  at Guangdong Pharmaceutical University, China

Lin Zhou is a distinguished professor in the Bioengineering Department at Guangdong Pharmaceutical University, China. With a strong background in carbohydrate engineering and fermentation technology, he has significantly contributed to the fields of bioactive substances, phytochemicals, and microbial metabolites. His research spans various biomedical applications, particularly in food science and chronic metabolic diseases. Having worked as a lecturer, associate professor, and professor at GDPU, he has led multiple national and industry-funded research projects. Lin Zhou’s expertise lies in antioxidant, anti-tumor, and anti-aging properties of bioactive substances. His scientific contributions are widely recognized, with numerous publications in high-impact journals. Apart from academia, he has experience in industrial fermentation engineering, reflecting his practical approach to biotechnology research. His work continues to influence advancements in pharmaceutical and food sciences, earning him prestigious awards in science and technology.

Professional Profiles📖

ORCID

Education 🎓

Ph.D. in Carbohydrate Engineering (2006) – South China University of Technology (SCUT), Guangzhou, China, under the guidance of Prof. Siyuan Guo.

Master to Ph.D. Direct Track (2001-2006) – South China University of Technology.

B.S. in Fermentation Engineering (1995-1999) – Hubei University of Technology (HBUT).

Work Experience💼

2018-2019 – Visiting Scholar, CSIRO, Melbourne, Australia.

2014-2017 – Postdoctoral Researcher, South China University of Technology.

2006-Present – Professor, Guangdong Pharmaceutical University.

2011-2012 – Scientific Special Commissioner, Guangdong Province.

2000-2001 – Workshop Manager, HeChengFeng Food and Beverage Ltd, China.

1999-2000 – Workshop Manager, ChuTe Food and Beverage Ltd, China.

Awards and Honors 🏆

First Prize in Science and Technology (2024) – Provincial High-Tech Enterprise Association, Guangdong, China.

Second Prize in Science and Technology (2024) – Provincial Light Industry Council, Guangdong, China.

Skills 💡

Bioactive Compound Analysis

Fermentation Technology

Microbial Metabolite Research

Pharmaceutical Biotechnology

Food Science and Engineering

Scientific Writing and Research Management

Innovation in Biopharmaceuticals

Research Focus 🔬

Lin Zhou specializes in the functional study of bioactive substances, emphasizing phytochemicals and microbial metabolites. His research explores the antioxidant, anti-tumor, and anti-aging potential of natural compounds, contributing to biomedical sciences. His work intersects microbiology, food science, and pharmaceuticals, leading industry-oriented research and collaborations. He has participated in China’s National Key R&D Program and led multiple industry-funded projects, making significant contributions to applied biotechnology.

Conclusion✅

Prof. Lin Zhou is a strong candidate for the Excellence in Innovation Award due to his extensive contributions to bioengineering, pharmaceutical sciences, and food biotechnology. His research has significantly advanced knowledge in metabolic disease treatment and bioactive substances, making him a worthy recipient of this recognition. Enhancing commercialization efforts and expanding global collaborations could further elevate his profile in scientific innovation.

Publications Top Notes📚

“Piggyback Crowdsensing (PCS): Energy Efficient Crowdsourcing of Mobile Sensor Data by Exploiting Smartphone App Opportunities”
Citations: 224
Year: 2013

“Cutting the Cord: A Robust Wireless Facilities Network for Data Centers”
Citations: 83
Year: 2014

“On the Validity of Geosocial Mobility Traces”
Citations: 78
Year: 2013

“Voting by Committees”
Citations: 435
Year: 1991

“On a Conjecture by Gale About One-Sided Matching Problems”
Citations: 357
Year: 1990

“A New Bargaining Set of an N-Person Game and Endogenous Coalition Formation”
Citations: 174
Year: 1994

“Atomic-Scale Characterization of Dilute Dopants in Topological Insulators via STEM–EDS Using Registration and Cell Averaging Techniques”
Year: 2024

“Sub-Lexical Phonological and Semantic Processing of Semantic Radicals: A Primed Naming Study”
Citations: 57
Year: 2013

“A Chinese Text Input Brain–Computer Interface Based on the P300 Speller”
Citations: 50
Year: 2012

“Pre-Lexical Phonological Processing in Reading Chinese Characters: An ERP Study”
Citations: 36
Year: 2014

“Measuring Megaregional Structure in the Pearl River Delta by Mobile Phone Signaling Data: A Complex Network Approach”
Citations: 76
Year: 2020

“Actors and Network in the Marketization of Rural Collectively-Owned Commercial Construction Land (RCOCCL) in China: A Pilot Case of Langfa, Beijing”
Citations: 31
Year: 2020

“Efficiency and Equality of the Multimodal Travel Between Public Transit and Bike-Sharing Accounting for Multiscale”
Citations: 10
Year: 2024